Veozah, Lynkuet, and menopause hormone therapy: compare the symptom target and monitoring

Veozah (fezolinetant) and Lynkuet (elinzanetant) are FDA-approved nonhormonal medicines for moderate to severe vasomotor symptoms due to menopause. They target hot flashes and night sweats through neurokinin pathways rather than supplying estrogen, and neither is a universal substitute for every menopause treatment. Their monitoring and interaction requirements differ, so the choice needs an exact-product review rather than a simple hormone-versus-no-hormone preference.¹²⁴

Start with the problem the prescription is supposed to solve

Identify the symptoms that are most disruptive and how they affect sleep or daily activities. A hot-flash treatment discussion is different from a discussion about vaginal symptoms, bone health, or another cause of disturbed sleep.

The Menopause Society distinguishes systemic hormone therapy from local vaginal treatment and emphasizes an individualized assessment.⁴ A nonhormonal vasomotor-symptom indication should not be expanded into a promise to address every concern discussed at a menopause visit.

Ask the clinician which symptoms belong to the proposed medicine’s target and which need a separate plan. That keeps a single prescription from becoming shorthand for comprehensive menopause care.

The two nonhormonal products are related, not identical

Veozah is an NK3 receptor antagonist. Lynkuet acts at NK1 and NK3 receptors. Both labels specify moderate to severe vasomotor symptoms due to menopause.¹²

FDA approved Lynkuet on October 24, 2025, based on its own clinical development program.³ Its later approval does not establish that it is better than Veozah or hormone therapy for an individual.

The table organizes choices for discussion. It is not a recommendation to start, combine, or switch medicines.

Liver monitoring is product-specific

Veozah carries a boxed warning for hepatotoxicity. Its current label calls for liver testing before treatment, monthly for the first three months, and at months six and nine, with additional action when indicated.¹

Lynkuet’s label calls for baseline hepatic evaluation and follow-up transaminase evaluation three months after initiation. It also has instructions for symptoms suggesting liver injury.² Do not assume the two products share one laboratory schedule because both are nonhormonal.

Ask who orders the tests, who reads the results, how an abnormal result reaches the prescriber, and what happens if testing cannot be completed. A subscription that supplies medication should explain the monitoring pathway, not leave it as an unassigned task.

Review the full medicine list, not just hormone use

Veozah is contraindicated with CYP1A2 inhibitors and in specified liver and kidney conditions.¹ Lynkuet has different interaction provisions involving CYP3A4, as well as precautions concerning CNS effects and seizures; pregnancy is contraindicated.²

Those enzyme names are prompts for professional medication reconciliation, not a consumer instruction to stop another prescription. Bring all medicines, supplements, and relevant medical history to the prescriber and pharmacist.

For Lynkuet, ask how possible daytime impairment fits driving, work, and other activities. For either product, obtain the current Medication Guide and understand the product-specific instructions for concerning symptoms rather than treating “no hormones” as “no monitoring.”

Do not rank the medicines from separate placebo trials

Different studies can enroll different participants, use different baselines, and assess outcomes at different times. FDA’s Lynkuet snapshot summarizes the trials supporting its approval; it is not a direct comparison against Veozah or hormone therapy.³

If a practice offers a superiority claim, ask for the actual comparative study and its endpoint. A reduction in symptom frequency, a severity score, and a sleep outcome should not be compressed into one universal winner.

The patient’s priorities still matter. Ask what improvement will be assessed, when the treatment will be reviewed, and what would count as insufficient benefit or unacceptable burden.

Keep hormone-label changes in their own context

Recent changes to particular hormone-product warnings do not alter the labels of Veozah or Lynkuet. The hormone-warning guide covers that separate regulatory record.

Similarly, a discussion about endometrial protection belongs to the actual systemic-estrogen regimen and uterus status; it should not be copied automatically onto every nonhormonal option.

A useful consultation ends with a defined symptom target, an explained product choice, a monitoring owner, and a reassessment plan. Those details make the decision more meaningful than choosing between the words “natural,” “new,” and “hormone-free.”